|Day Low/High||80.77 / 81.46|
|52 Wk Low/High||67.88 / 88.48|
I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.
Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.
Eli Lilly's (LLY) olaratumab drug for soft tissue sarcoma was recommended for approval by the European Medicines Agency on Friday.
Aggressive 8-point plan to help safeguard animal and human health makes progress, creates pipeline of alternatives to shared-class antibiotics
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
I like a bearishly biased, slightly-out-of-the-money vertical put spread.
Eli Lilly's (LLY) stock rating was lifted to 'overweight' from 'neutral' at JPMorgan on Thursday morning.
Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
It's time to unload these toxic stocks from your portfolio.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.
Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.
Documentary chronicles the journey of two Canine Assistants recipients as they develop unbreakable bonds with their dogs
The market action looks very much like it did before the drops that occurred in 2000 and 2008.
Jim Cramer says Eli Lilly has been overpromising and underdelivering.